Erratum: Antiproliferative and Proapoptotic Effects of Topotecan in Combination With Thymoquinone on Acute Myelogenous Leukemia (Clinical Lymphoma, Myeloma and Leukemia 14S 10.1016/j.clml.2014.04.014);Antiproliferative and proapoptotic effects of topotecan in combination with thymoquinone on acute myelogenous leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue , 2014, Pages S46-S55

  Khalife, Rana ^a   Stephany, El Hayek ^a   Tarras, Omayr ^a   Hodroj, Mohammad Hassan ^a   Rizk, Sandra ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

AML; Anticancer; Apoptosis; Combined therapy; p53

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; THYMOQUINONE; TOPOTECAN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL LINE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, MYELOID, ACUTE; SIGNAL TRANSDUCTION; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84937900330     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.05.002     Document Type: Erratum

References (48)

1. S. Tsunetoh, Y. Teraj, H. Sasaki, and et al. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers Cancer Biol Ther 10 2010 1137 1146
2. K. Paik, M. Rudin, A. Brown, and et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies Cancer Chemother Pharmacol 66 2010 1079 1085
3. P. Hertzberg, J. Caranfa, and M. Hecht On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex Biochemistry 28 1989 4629 4638
4. H. Hsiang, R. Hertzberg, S. Hecht, and F. Liu Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J Biol Chem 260 1985 14873 14878
5. S. Tsang, T. Cheuk, R. Chen, and et al. Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma BMC Cancer 12 2012 101 111
6. C. Kollmannsberger, K. Mross, A. Jakob, L. Kanz, and C. Bokemeyer Topotecan, a novel topoisomerase I inhibitor: pharmacology and clinical experience Oncology Basel 56 1999 1 12
7. H.M. Kantarjian, M. Beran, A. Ellis, and et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia Blood 81 1993 1146 1151
8. M. Chintagumpala, S. Friedman, F. Stewart, and et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group J Neurooncol 77 2006 193 198
9. J. Fassberg, and I. Stella A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues J Pharm Sci 81 1992 676 684
10. S. Hawkins, S. Bradfield, A. Whitlock, and et al. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study Pediatr Blood Cancer 47 2006 790 794
11. G. Klautke, M. Schutze, I. Bombor, R. Benecke, J. Piek, and R. Fietkau Concurrent chemoradiotherapy and adjuvant chemotherapy with topotecan for patients with glioblastoma multiforme J Neurooncol 77 2006 199 205
12. J. Adams, M. Sandvold, F. Myhren, T. Jacobsen, F. Giles, and D. Rizzieri Anti proliferative activity of ELACYTTM (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells Leuk Lymphoma 49 2008 786 797
13. F. Holcombe, M. Kong, and D. Wimmer Combined topoisomerase I inhibition for the treatment of metastatic colon cancer Anticancer Drugs 15 2004 569 574
14. S. Fulda, and M. Debatin Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy Oncogene 25 2006 4798 4811
15. K. Cain, B. Bratton, C. Langlais, and et al. Apaf-1 oligomerizes into biologically active ∼700-kDa and inactive ∼1.4-MDa apoptosome complexes J Biol Chem 275 2000 6067 6070
16. S. Padhye, S. Banerjee, A. Ahmad, R. Mohammad, and H. Sarkar From here to eternity - the secret of Pharaohs: therapeutic potential of black cumin seeds and beyond Cancer Ther 6 2008 495 510
17. B.H. Ali, and G. Blunden Pharmacological and toxicological properties of Nigella sativa. Phytother Res 17 2003 299 305
18. S.O. Arslan, E. Gelir, F. Armutcu, and et al. The protective effect of thymoquinone on ethanol-induced acute gastric damage in the rat Nutr Res 25 2005 673 680
19. S. Al-Ghamdi The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa J Ethnopharmacol 76 2001 45 48
20. A. Al-Hader, A. Aqel, and Z. Hassan Hypogycemic effects of the volatile oil of Nigella sativa seeds Int J Pharmacol 31 1993 96 100
21. N. Chakravorty Inhibition of histamine release from mast cells by nigellone Ann Allergy 70 1993 237 242
22. A. Khan, K. Ashfaq, S. Zuberi, S. Mahmood, and H. Gilani The in vivo antifungal activity of the aqueous extract from Nigella sativa seeds Phytother Res 17 2003 183 186
23. R. Worthen, A. Ghosheh, and A. Crooks The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L Anticancer Res 18 1998 1527 1532
24. A. Zaoui, Y. Cherrah, A. Lacaille-Dubois, and et al. Diuretic and hypotensive effects of Nigella sativa in the spontaneously hypertensive rat Therapie 55 2000 379 382
25. S. Zedlitz, R. Kaufmann, and H. Boehncke Allergic contact dermatitis from black cumin (Nigella sativa) oil-containing ointment Contact Dermatitis 46 2002 188 189
26. S. Banerjee, O. Kaseb, A. Wang, and et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer Cancer Res 69 2009 5575 5583
27. H. Gali-Muhtasib, M. Diab-Assaf, C. Boltze, and et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism Int J Oncol 25 2004 857 866
28. H. Gali-Muhtasib, G. Abou Kheir, A. Kheir, N. Darwiche, and A. Crooks Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes Anticancer Drugs 15 2004 389 399
29. I. Norsharina, I. Maznah, A. Aied, and A. Ghanya Thymoquinone rich fraction from Nigella sativa and thymoquinone are cytotoxic towards colon and leukemic carcinoma cell lines J Med Plants Res 5 2011 3359 3366
30. M. Roepke, A. Diestel, K. Bajbouj, and et al. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells Cancer Biol Ther 6 2007 160 169
31. M. Shoieb, M. Elgayyar, S. Dudrick, L. Bell, and K. Tithof In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone Int J Oncol 22 2003 107 113
32. H. Jafri, J. Glass, R. Shi, O. Zhang, M. Prince, and K. Hancock Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo J Exp Clin Cancer Res 29 2010 87 98
33. T. Yi, S. Cho, S. Yi, and et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and ERK signaling pathways Mol Cancer Ther 7 2008 1789 1796
34. T. Tomicic, M. Christmann, and B. Kaina Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival Cancer Res 65 2005 8920 8926
35. T. Miyashita, and C. Reed Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 80 1995 293 299
36. M. Muller, S. Wilder, D. Bannasch, and et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs J Exp Med 188 1998 2033 2045
37. D. Lackinger, U. Eichhorn, and B. Kaina Effect of ultraviolet light, methyl methanesulfonate and ionizing radiation on the genotoxic response and apoptosis of mouse fibroblasts lacking c-Fos, p53 or both Mutagenesis 16 2001 233 241
38. D. Lackinger, and B. Kaina Primary mouse fibroblasts deficient for c-Fos, p53 or for both proteins are hypersensitive to UV light and alkylating agent-induced chromosomal breakage and apoptosis Mutat Res 457 2000 113 123
39. L. Smith, M. Ford, C. Hollander, and et al. p53- mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes Mol Cell Biol 20 2000 3705 3714
40. G. Ferreira, W. Span, J. Peters, E. Kruyt, and G. Giaccone Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria controlled manner in the non-small cell lung cancer cell line NCI-H460 Cancer Res 60 2000 7133 7141
41. A. Wirries, S. Breyer, K. Quint, R. Schobert, and M. Ocker Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells Exp Ther Med 1 2010 369 375
42. O. Kaseb, K. Chinnakannu, D. Chen, and et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer Cancer Res 67 2007 7782 7788
43. I. Petak, M. Tillman, G. Harwood, R. Mihalik, and A. Houghton Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells Cancer Res 60 2000 2643 2650
44. P. D'Arpa, C. Beardmore, and F. Liu Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons Cancer Res 50 1990 6919 6924
45. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells Cancer Res 56 1996 4430 4437
46. H. Hsiang, G. Lihou, and F. Liu Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin Cancer Res 49 1989 5077 5082
47. G. Shao, X. Cao, H. Zhang, W. Kohn, S. Wold, and Y. Pommier Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes Embo J 18 1990 1397 1406
48. A. Nakashio, N. Fujita, S. Rokudai, S. Sato, and T. Tsuruo Signaling pathway during topotecan-induced apoptosis prevention of phosphatidylinositol 3'-kinase-Akt survival Cancer Res 60 2000 5303 5309